ABSTRACT
Bioaerosols are present everywhere around us, either on surfaces or in the air. Depending on their nature, these bioaerosols have positive or negative impacts on our bodies. Our immune system always creates a balance in our health system in response to these bioaerosols. If our body's immune system is compromised for a while, it could have many severe health complications. A good example is in patients who recovered from COVID-19 during the COVID-19 pandemic. During treatment, many drugs like dexamethasone, tocilizumob, itolizumab, and steroids were extensively used that suppressed the immune system, resulting in many fungal infections. In this review, we summarise the various studies carried out throughout the globe regarding fungal infection, including Mucormycetes (black fungus), Candida spp., Aspergillus fumigatus, and pneumocystis jirovecii. The patient disease history and treatment details were also examined so as to develop the risk of mortality. Populations with other pre-existing diseases such as diabetes and asthma are more vulnerable to infection. These infections spread at a very high rate and have a high risk of mortality in patients who have recovered from COVID-19. Earnest attention is needed regarding the treatment procedure of COVID-19 patients and for the follow-up of recovered patients. Here, we suggest some treatment methods that will help prevent infection in patients who have recovered from COVID-19 or in immunosuppressed bodies. [ FROM AUTHOR] Copyright of COVID is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
This systematic review focuses on the clinical features, physical examination findings, outcomes, and underlying pathology of acute telogen effluvium (TE), a type of diffuse hair loss, occurring in coronavirus disease 2019 (COVID-19) recovered patients. MEDLINE/PubMed and Embase databases were queried till October 2021 to identify studies reporting acute TE occurring after COVID-19 recovery. Data were obtained from 19 studies, which included 465 patients who were diagnosed with acute TE. The median age of these patients was 44 years and 67.5% were females. The most common trichoscopic findings were decreased hair density, the presence of empty follicles, or short regrowing hair. The mean duration from COVID-19 symptom onset to the appearance of acute TE was 74 days, which is earlier than classic acute TE. Most patients recovered from hair loss, while a few patients had persistent hair fall. Our results highlight the need to consider the possibility of post-COVID-19 acute TE in patients presenting with hair fall, with a history of COVID-19 infection, in the context of COVID-19 pandemic. Despite being a self-limiting condition, hair loss post-COVID-19 is a stressful manifestation. Identifying COVID-19 infection as a potential cause of acute TE will help the clinicians counsel the patients, relieving them from undue stress.